ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice

Blood

Volumn 127, Issue 4, 2016, Pages 426-435

  Rood, Julia E ^a,b   Rao, Sheila ^a,b   Paessler, Michele ^a   Kreiger, Portia A ^c   Chu, Niansheng ^a   Stelekati, Erietta ^b   Wherry, E John ^b   Behrens, Edward M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; ST2 PROTEIN; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; MYD88 PROTEIN, MOUSE; PERFORIN; PERFORIN 1, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HEMOPHAGOCYTIC SYNDROME; LYMPHOCYTOPOIESIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PATHOLOGY; VIROLOGY;

ANIMALS; ANTIBODIES, BLOCKING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENE DELETION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; PERFORIN; RECEPTORS, INTERLEUKIN;

EID: 84958078451     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-659813     Document Type: Article

References (43)

1. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-1959.
2. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263-280.
3. Pachlopnik Schmid J, Côte M, Ménager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev. 2010;235(1):10-23.
4. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD81 T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-743.
5. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood. 2011;118(3):618-626.
6. Matloubian M, Suresh M, Glass A, et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 1999;73(3):2527-2536.
7. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8 (1) T cells and dendritic cells. Blood. 2013;121(26):5184-5191.
8. Trizzino A, zur Stadt U, Ueda I, et al; Histiocyte Society HLH Study group. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet. 2008;45(1):15-21.
9. Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood. 2011;117(24):6582-6588.
10. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem. 2012;287(9):6941-6948.
11. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One. 2008;3(10):e3331.
12. Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188(7):3488-3495.
13. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-490.
14. Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol. 2012;33(8):389-396.
15. Lüthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84-98.
16. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021-9026.
17. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9(1):143-150.
18. Ngoi SM, St Rose M-C, Menoret AM, et al. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci USA. 2012;109(26):10486-10491.
19. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med. 1984;160(2):521-540.
20. National Center for Biotechnology Information. GEO: Gene expression omnibus. http://www.ncbi. nlm.nih.gov/geo/, GSE26050. Accessed September 28, 2015.
21. National Center for Biotechnology Information. GEO: Gene expression omnibus. http://www.ncbi. nlm.nih.gov/geo/, GSE21521. Accessed September 28, 2015.
22. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127.
23. Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60(3):738-749.
24. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. 2014; arXiv:1406.5823v1 [stat. CO].
25. Levy R. Using R formulae to test for main effects in the presence of higher-order interactions. 2014; arXiv:1405.2094v1 [stat. ME].
26. Bonilla WV, Fröhlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8. T cell responses. Science. 2012;335(6071):984-989.
27. Baumann C, Bonilla WV, Fröhlich A, et al. T-betand STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA. 2015;112(13):4056-4061.
28. Sumegi J, Barnes MG, Nestheide SV, et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011;117(15):e151-e160.
29. Hinze CH, Fall N, Thornton S, et al. Immature cell populations and an erythropoiesis geneexpression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12(3):R123.
30. Jessen B, Kögl T, Sepulveda FE, de Saint Basile G, Aichele P, Ehl S. Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front Immunol. 2013;4:448.
31. Yang Q, Li G, Zhu Y, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD81 T cells. Eur J Immunol. 2011;41(11):3351-3360.
32. Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 2009;39(4):1046-1055.
33. Chiossone L, Audonnet S, Chetaille B, et al. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol. 2012;3:239.
34. Jung A, Kato H, Kumagai Y, et al. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol. 2008;82(1):196-206.
35. Kägi D, Hengartner H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol. 1996;8(4):472-477.
36. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol. 2011;186(7):4375-4387.
37. Rahman AH, Cui W, Larosa DF, et al. MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol. 2008;181(6):3804-3810.
38. Rahman AH, Zhang R, Blosser CD, et al. Antiviral memory CD8 T-cell differentiation, maintenance, and secondary expansion occur independently of MyD88. Blood. 2011;117(11):3123-3130.
39. Browne SK, Holland SM. Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol. 2010;10(6):534-541.
40. Dorman SE, Holland SM. Interferon-g and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000;11(4):321-333.
41. Tesi B, Sieni E, Neves C, et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-g receptor deficiency. J Allergy Clin Immunol. 2015;135(6):1638-1641. e5.
42. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107(43):18581-18586.
43. Zhang Y, Zhang C, Zhuang R, et al. IL-33/ST2 correlates with severity of haemorrhagic fever with renal syndrome and regulates the inflammatory response in Hantaan virus-infected endothelial cells. PLoS Negl Trop Dis. 2015;9(2):e0003514